{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:05:51Z","timestamp":1790366751763,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.07.025","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:08:25Z","timestamp":1784560105000},"page":"1921-1932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world assessment of adherence to inclisiran dosing schedule and LDL-C reduction in patients with hypercholesterolemia in Austria"],"prefix":"10.1016","volume":"20","author":[{"given":"Dieter","family":"P\u00e4tzold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Vonbank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Clodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Ebenbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ail\u00eds","family":"Fagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Farries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Hofst\u00e4tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Nitzlader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6474-2789","authenticated-orcid":false,"given":"Doris","family":"Gangl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-3881","authenticated-orcid":false,"given":"Christopher","family":"Adlbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.07.025_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.903126","article-title":"Global burden attributable to high low-density lipoprotein-cholesterol from 1990 to 2019","volume":"9","author":"Du","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2026.07.025_bib2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s41043-025-01054-3","article-title":"Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis","volume":"44","author":"Ballena-Caicedo","year":"2025","journal-title":"J Health Popul Nutr"},{"issue":"139","key":"10.1016\/j.jacl.2026.07.025_bib3","first-page":"E1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"2019","author":"Grundy","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.jacl.2026.07.025_bib4","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.025_bib5","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","article-title":"LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals","volume":"134","author":"Underberg","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jacl.2026.07.025_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-073125","article-title":"Exploring barriers and facilitators of primary care physicians towards optimising statin therapy in patients with hyperlipidaemia in the very high-risk group: a qualitative study in Singapore","volume":"13","author":"Beh","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacl.2026.07.025_bib7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","article-title":"Adherence to high-intensity statins following a myocardial infarction hospitalization among medicare beneficiaries","volume":"2","author":"Colantonio","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2026.07.025_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/VHRM.S158641","article-title":"S. Nonadherence to statins: individualized intervention strategies outside the pill box","volume":"14","author":"Lansberg","year":"2018","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jacl.2026.07.025_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.07.025_bib10","article-title":"There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: a review of current practice and recommendations for improved effectiveness","volume":"12","author":"Makover","year":"2022","journal-title":"Am J Prevent Cardiol"},{"key":"10.1016\/j.jacl.2026.07.025_bib11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"140","key":"10.1016\/j.jacl.2026.07.025_bib12","first-page":"E596","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"2019","author":"Arnett","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.jacl.2026.07.025_bib13","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-section obserational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.07.025_bib14","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health-Eu"},{"key":"10.1016\/j.jacl.2026.07.025_bib15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00508-021-01978-w","article-title":"Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?: Results from the DA VINCI study","volume":"134","author":"Siostrzonek","year":"2022","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jacl.2026.07.025_bib16","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jacl.2026.07.025_bib17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jacl.2026.07.025_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endo"},{"key":"10.1016\/j.jacl.2026.07.025_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10557-022-07413-0","article-title":"Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10, and ORION-11 phase 3 randomized controlled trials","volume":"38","author":"Koenig","year":"2024","journal-title":"Cardiovasc Drug Ther"},{"key":"10.1016\/j.jacl.2026.07.025_bib20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.07.025_bib21","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacl.2026.07.025_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.clinthera.2023.12.003","article-title":"First report of inclisiran utilization for hypercholesterolemia treatment in real-world clinical settings in a Middle East population","volume":"46","author":"Iqbal","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2026.07.025_bib23","article-title":"Retrospective evaluation of LDL-C levels following first treatment with inclisiran as part of secondary prevention ASCVD risk reduction in a real-world primary care setting","volume":"15","author":"Deaney","year":"2024","journal-title":"J Prim Care Communit"},{"key":"10.1016\/j.jacl.2026.07.025_bib24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2024.10.106","article-title":"Real-world efficacy and safety of inclisiran: a single-country, multicenter, observational study (CHOLINET registry)","volume":"85","author":"Gargiulo","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.07.025_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.athplu.2025.01.001","article-title":"\"Inclisiran: early LDL-C target achievement in a real-life population\"","volume":"59","author":"Briani","year":"2025","journal-title":"Atheroscler Plus"},{"key":"10.1016\/j.jacl.2026.07.025_bib26","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1016\/j.jacl.2024.05.003","article-title":"Lipid-lowering therapy with inclisiran in the real-world setting: initial data from a national health care service","volume":"18","author":"Naoum","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.07.025_bib27","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1093\/eurheartj\/ehac653","article-title":"Inclisiran in primary prevention: reality or fiction?","volume":"43","author":"Gencer","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.025_bib28","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jacc.2024.03.402","article-title":"Early inclisiran use in atherosclerotic cardiovascular disease","volume":"83","author":"Shapiro","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.07.025_bib29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-023-01752-4","article-title":"Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease","volume":"22","author":"Nishikido","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacl.2026.07.025_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care - the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.07.025_bib31","unstructured":"Brunson JC, Read QD, ggalluvial: Alluvial Plots in 'ggplot2'. Retrieved from https:\/\/cran.r-project.org\/package=ggalluvial."},{"key":"10.1016\/j.jacl.2026.07.025_bib32","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.21105\/joss.02017","article-title":"ggalluvial: layered grammar for alluvial plots","volume":"5","author":"Brunson","year":"2020","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.jacl.2026.07.025_bib33","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.2021. Retrived from https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.jacl.2026.07.025_bib34","unstructured":"Dachverband der Sozialversicherungstr\u00e4ger. Erstattungskodex (EKO). Vienna, Austria: Dachverband der Sozialversicherungstr\u00e4ger; 2025. Available from: Austrian Social Insurance EKO Portal. Accessed July 18, 2025."},{"key":"10.1016\/j.jacl.2026.07.025_bib35","unstructured":"EPAR - Product Information. Amsterdam, The Netherlands: European Medicines Agency; 2022. Available from: EMA Leqvio EPAR Product Information. Accessed January 2025."},{"key":"10.1016\/j.jacl.2026.07.025_bib36","first-page":"e73","article-title":"Characterization of inclisiran use in real world: prescription data from Germany","volume":"16","author":"Klebs","year":"2022","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"key":"10.1016\/j.jacl.2026.07.025_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/circ.148.suppl_1.16180","article-title":"Abstract 16180: the adherence and LDL-C lowering effect of inclisiran among patients who received treatment at outpatient clinics","volume":"148","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.07.025_bib38","first-page":"1290","article-title":"Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy","volume":"19","author":"Engebretsen","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jacl.2026.07.025_bib39","doi-asserted-by":"crossref","DOI":"10.48101\/ujms.v129.9618","article-title":"A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels","volume":"129","author":"Svensson","year":"2024","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.jacl.2026.07.025_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00508-023-02245-w","article-title":"Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study","volume":"136","author":"Ebenbichler","year":"2024","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jacl.2026.07.025_bib41","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/03007995.2020.1786678","article-title":"Efficacy and tolerability of alirocumab in Austrian clinical practice - results of the non-interventional PEARL-AT study","volume":"36","author":"Leitner","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2026.07.025_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf214","article-title":"Efficacy and safety of inclisiran based on background lipid-lowering treatment","author":"Landmesser","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.07.025_bib43","first-page":"1941","article-title":"Reductions in LDL-C within the first year of treatment with inclisiran: results from a multicenter real world cohort","volume":"83","author":"Ballantyne","year":"2024","journal-title":"J\u00a0Am\u00a0Coll\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.07.025_bib44","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.atherosclerosis.2023.06.277","article-title":"Current LDL-C Management in Germany - the victorion-implement study","volume":"379","author":"Weing\u00e4rtner","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.07.025_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119586","article-title":"Real-world adherence, LDL-C lowering effect and goal-attainment of inclisiran in Belgian patients with atherosclerotic cardiovascular disease: the BE.REAL registry","volume":"407","author":"Demeure","year":"2025","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:57:01Z","timestamp":1790366221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1933287426004551"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.025","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world assessment of adherence to inclisiran dosing schedule and LDL-C reduction in patients with hypercholesterolemia in Austria","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}